Costs associated with adverse events from remission induction for children with Acute Lymphoblastic Leukemia (ALL)

Costs associated with adverse events from remission induction for children with Acute Lymphoblastic Leukemia (ALL)

Abstract Background ALL is the most frequent hematological tumor in children, so during remission induction chemotherapy protocol (RICP) adverse events (AEs) may appear. The public program in Mexico in charge of financial support to oncologic children without social security delivered a fix amount f...

Full description

Bibliographic Details
Main Authors: Eréndira Mejía-Aranguré, Alfonso Reyes-López, Luis Enrique Juárez-Villegas, Yosef Olaf Hernández-Olivares, Alberto Daniel Saucedo-Campos, Gabriela Hernández-Pliego, Silvia Martínez-Valverde, Leticia A. Barajas-Nava, Juan Garduño-Espinosa
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Health Services Research
Subjects:
Children
Cost
Adverse event
Leukemia
Chemotherapy
Toxicity
Online Access:https://doi.org/10.1186/s12913-022-08676-x

Internet

https://doi.org/10.1186/s12913-022-08676-x

Similar Items